Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens.

European journal of haematology - 1 Aug 2026

Caserta Santino, Martino Enrica Antonia, Lofaro Danilo, Vigna Ernesto, Bruzzese Antonella, Mendicino Francesco, Alvaro Maria Eugenia, Labanca Caterina, Lucia Eugenio, Olivito Virginia, Amodio Nicola, Morabito Fortunato, Gattei Valter, Gentile Massimo

Abstract excerpt

Immunoglobulin heavy chain variable region-unmutated (IGHV-U) chronic lymphocytic leukemia (CLL) represents a biologically aggressive subgroup with limited responsiveness to chemoimmunotherapy (CIT). To clarify the comparative effectiveness of available frontline options, we conducted a comprehensive Bayesian network meta-analysis of randomized clinical trials including more than 4500 IGHV-U patients. Targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Immunoglobulin Heavy Chains

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunoglobulin Variable Region

Share to Immunotherapy

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Molecular Targeted Therapy

Share to Mutation

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41981887
DOI: 10.1111/ejh.70191
PMCID: PMC13326791

Genes

CIT
BTK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens.PMID 41981887Read ↗

Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.Semantic proximity Read ↗

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.Semantic proximity Read ↗

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.Semantic proximity Read ↗

How should we sequence and combine novel therapies in CLL?Semantic proximity Read ↗

Chronic lymphocytic leukemia treatment algorithm 2022.Semantic proximity Read ↗

Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.Semantic proximity Read ↗

Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.Semantic proximity Read ↗

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.Semantic proximity Read ↗

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.Semantic proximity Read ↗

Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.